NSAIDs: the Emperor’s new dogma?
Open Access
Abstract
The spectacular marketing success of the selective cyclooxygenase 2 (COX-2) inhibitors is largely based on efficacy comparable with conventional non-steroidal anti-inflammatory drugs (NSAIDs) with vastly improved gastrointestinal safety. The additional key to the marketing success is the purity and simplicity of the message—that is, COX-1 inhibition causes the gastrointestinal side effects of NSAIDs (COX-1 dogma) while COX-2 blocking confers the therapeutic benefits (COX-2 dogma). Adherence to the COX dogmas with development of COX-2 selective agents has undoubtedly benefited many patients, but ironically their scientific basis is now seriously challenged by experimentation.Keywords
This publication has 32 references indexed in Scilit:
- Differential effect of FR122047, a selective cyclo‐oxygenase‐1 inhibitor, in rat chronic models of arthritisBritish Journal of Pharmacology, 2002
- Cyclooxygenase-2—10 Years LaterThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Inflammatory bowel disease and spondylarthropathyArthritis & Rheumatism, 2001
- Effects of specific inhibition of cyclo‐oxygenase‐1 and cyclo‐oxygenase‐2 in the rat stomach with normal mucosa and after acid challengeBritish Journal of Pharmacology, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacinGut, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID‐enteropathy in the ratAlimentary Pharmacology & Therapeutics, 2000
- Anti-inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid ArthritisJAMA, 1999
- COX-2 inhibitorsThe Lancet, 1999